Global Aplastic Anemia Treatment Market Highlights over 2022 – 2030
The global aplastic anemia treatment market is estimated to grow at a CAGR of ~5% over the forecast period, i.e., 2022 – 2030. Aplastic anemia is a rare genetic condition in which your body stops producing enough new blood cells. The growth of the market can be attributed to the increasing prevalence of aplastic anemia is estimated to boost the market growth. According to the National Organization for Rare Disorders (NORD), in the United States approximately 500-1,000 new cases of aplastic anemia are diagnosed each year, 4-6 cases in a million in Asia, and 2-3 cases in a million in Europe. Aplastic anemia is a type of aplasia, which is why, there is no cure available for this disease. Absence of aplasia treatment is estimated to boost the market growth. Moreover, the growing medical R&D activities aiming to develop treatment drugs for rare diseases, along with the growing investment in the field of research, are projected to boost the market growth. According to the World Bank data, 2.204% of the global GDP was spent for R&D activities in 2018.
Get more information on this report: Download Sample PDF
The market is divided by disease type into acquired aplastic anemia and inherited aplastic anemia, out of which, the inherited aplastic anemia segment is anticipated to hold the notable share in the global aplastic anemia treatment market over the forecast period on account of high prevalence of this disorder amongst infants. Acquired aplastic anemia is more common in adults, while inherited aplastic anemia is prevalent in children.
On the basis of treatment type, the market is segmented into stem cell therapy, blood transfusion, drug therapy, and others, out of which, the stem cell therapy segment is projected to gain the highest revenue share during the forecast period. The growth of the segment can be attributed to the high success rate of stem cell therapy, in which, bone marrow is transfused to treat the lack of new blood cells.
Major Macro-Economic Indicators Impacting the Market Growth
According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.
Global Aplastic Anemia Treatment Market Regional Synopsis
On the basis of geographical analysis, the global aplastic anemia treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in Asia Pacific region is estimated to witness noteworthy growth over the forecast period on the back of improving healthcare facilities, and economic development in countries, including, China, India, Japan, and others.
The market in the North America region is anticipated to gain the largest market share throughout the forecast period on the account of high cases of aplastic anemia in the region, growing healthcare expenditure, and increasing investment in medical research activities. According to the data by the World Bank, North America spent 2.734% of its GDP for R&D activities in 2018.
Get more information on this report: Download Sample PDF
The global aplastic anemia treatment market is further classified on the basis of region as follows:
Our in-depth analysis of the global aplastic anemia treatment market includes the following segments:
By Treatment Type
By Disease Type
By Route of Administration
Top Featured Companies Dominating the Market
FREQUENTLY ASKED QUESTIONS
The increasing prevalence of aplastic anemia, and growing medical research activities to boost the market growth.
The market is anticipated to attain a CAGR of ~5% over the forecast period, i.e., 2022 – 2030.
The major players in the market are Eisai Co., Ltd., Allergan, Inc., TauRx Therapeutics Ltd., AbbVie Inc., Novartis AG, Siemens Healthcare GmbH, Pfizer, Inc., Bristol-Myers Squibb Company, Bayers AG, and others.
The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.
The market is segmented by treatment type, disease type, route of administration, end-user, and by region.
The stem cell transplant segment is anticipated to hold largest market size over the forecast period and display significant growth opportunities.
The high cost of treatment is estimated to hamper the market growth.
The North America region is anticipated to provide more business opportunities over the forecast period on account of efficient healthcare sector, along with growing R&D expenditure in the region.
Select License Type
Direct access to analyst to help you understand the market in a better way to handle your critical question
Citing your business specific requirement our consultant would assist you ensuring targeted goal is achieved
Get 10% free customization